Meeting
2022 ASCO Genitourinary Cancers Symposium
CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.
Authors
Matthew Raymond Smith
Massachusetts General Hospital, Boston, MA
Matthew Raymond Smith , Neeraj Agarwal , Tilman Todenhöfer , Josep M. Piulats , Jae-Lyun Lee , Redas Trepiakas , Arpit Rao , Lisa Horvath , Andrew Lithio , Erica L. Johnston , Maarten Hulstijn , Karim Nacerddine , Christopher Sweeney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03706365
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr TPS198)
DOI
10.1200/JCO.2022.40.6_suppl.TPS198
Abstract #
TPS198
Poster Bd #
P11
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
CYCLONE 2: A phase II, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.
First Author: Matthew Raymond Smith
Poster
2015 ASCO Annual Meeting
The PRESIDE trial: A randomized, double-blind, placebo-controlled phase III efficacy and safety study of continued enzalutamide plus docetaxel after disease progression on enzalutamide alone in patients with metastatic castration-resistant prostate cancer.
First Author: Simon Chowdhury
Poster
2021 ASCO Annual Meeting
CYCLONE 1: A phase 2 study of abemaciclib in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a novel hormonal agent and taxane-based chemotherapy.
First Author: Neeraj Agarwal
Poster
2022 ASCO Annual Meeting
PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Shahneen Sandhu